From Products to Protocols: The Next Evolution of Consumer Health

Beauty brands are launching AI skin diagnostics. Longevity clinics are running full-body MRIs, epigenetic clocks, and continuous glucose monitors. Wellness companies are pouring venture capital into personalisation engines that can tailor a supplement stack or a skincare routine down to an individual's genome. By almost every measure, the science, the data, and the technology behind consumer health have never been more sophisticated.

And yet the industry keeps running into the same wall: people don't do the thing.

They buy the device and stop wearing it after six weeks. They fill the prescription and stop refilling it within a year. They join the longevity programme with great intentions and quietly disengage before the second quarterly check-in. The gap between what science says will work and what people actually sustain is no longer a marketing problem; it is the problem. And it points to a structural shift that beauty, wellness, and longevity brands can no longer ignore: the winners of the next decade won't be the ones with the best product. They'll be the ones who can engineer adherence —turning good protocols into lived, repeated behaviour.

Why Information Alone Doesn't Change Behaviour

The beauty and wellness industry has largely operated on an "educate, and they will follow" assumption: give the consumer the diagnostic result, the ingredient science, the personalised plan, and behaviour change will follow naturally. The data on human behaviour tells a very different story.

Even in a domain where the stakes are life and death and the "protocol" is prescribed by a physician, adherence collapses. The World Health Organisation’s landmark review found that adherence to long-term therapies in developed countries averages only 50%, and is markedly lower in developing countries, even when patients fully understand their diagnosis and treatment (WHO). A more recent 2025 review of the clinical and economic consequences of non-adherence confirms the number has barely moved in two decades, and estimates that poor medication adherence contributes to roughly 200,000 preventable deaths and €125 billion in avoidable healthcare spending in Europe every year (PMC, 2025).

If knowledge and even medical authority aren't enough to keep someone taking a life-saving pill, it is naïve to assume a skincare routine, a fasting protocol, or a longevity membership will fare better on information alone. The newest and most visible proof point is GLP-1 therapy: despite dramatic, visible results, real-world data from Denmark showed 52% of adults discontinued semaglutide for weight loss within a year, with 18% stopping by three months (Medscape). A Cleveland Clinic study published in 2025 found that patients who discontinued treatment early lost roughly a third of the weight of those who stayed the course - 3.6% versus 11.9% body weight at one year (Cleveland Clinic). The molecule works. The follow-through doesn't. That is the entire thesis of this piece in one data point.

The Psychology of Adherence: Why Consumers Abandon Routines

Adherence research consistently points to the same failure modes, and they are strikingly consistent across medicine, fitness, and beauty:

• Goals are vague and unsustainable. Research on New Year's resolutions — a useful proxy for any self-directed health protocol — found that vague goals such as "get fit" were abandoned far more often than specific, scheduled ones, and that roughly 64% of resolutions collapse within the first month (PsychNewsDaily / Edith Cowan University).
• Habits take longer to form than the "21 days" myth suggests. A 2024 systematic review and meta-analysis of health-related habit formation found the median time to reach automaticity was 59–66 days, with high individual variability (4 to 335 days) — meaning most consumer engagement windows (a 30-day challenge, a single product cycle) end before the habit has actually taken hold (PubMed, 2024).
• Willpower is a depleting resource, not a personality trait. Protocols that depend on daily willpower rather than environmental design or social structure fail predictably once novelty fades and life gets in the way.
• Cost, complexity, and side effects compound over time. In the GLP-1 data, out-of-pocket costs, side effects, and “perceived completion” (the belief that the job is done once early results appear) were the leading drivers of discontinuation (Truveta, ISPOR 2025; JAMA Network Open).

None of this is a motivation problem. It's a design problem — and design is something beauty and wellness brands are, in principle, very good at.

Stress, the Brain, and the Collapse of Good Intentions

There is a neurological reason adherence breaks down precisely when it matters most. A widely covered 2025 study in Nature identified two "dials" in the brain that explain how chronic stress hijacks decision-making: prolonged stress dials back deliberate, goal-directed thinking while amplifying a rigid, habit-driven "autopilot" mode (Nature). This builds on earlier human research published in Translational Psychiatry, which showed that chronic stress biases decision-making toward old habits and makes people insensitive to the actual outcomes of their choices — although the effect is reversible once stress subsides (Nature/Translational Psychiatry).

In practice, this means the moments when a consumer most needs to stick to a new skincare regimen, a metabolic protocol, or a longevity intervention a stressful work week, a health scare, a life transition are precisely the moments the brain reverts to old, familiar behaviour instead of the new one. Stress doesn't just make people "less motivated"; it neurologically reroutes decision-making away from newly formed protocols and back to autopilot. Any consumer health model that doesn't account for this will lose exactly the customers who need it most, exactly when they need it most.

What Beauty Brands Can Learn From Medical Adherence

Medicine has spent decades studying non-adherence because the cost of failure is measured in lives and billions of euros, and some of its lessons translate directly to beauty and aesthetics:

1. Simplicity beats sophistication. The more complex a regimen, the lower the adherence this holds for multi-drug regimens and for eleven-step skincare routines alike.
2. Early wins matter disproportionately. GLP-1 data shows that every percentage point of early weight loss reduced the odds of discontinuation (JAMA Network Open) — beauty brands that can engineer a visible, fast, credible first result buy themselves months of continued use.
3. Side effects and friction, not lack of belief, drive dropout. In the largest real-world dataset, adverse effects were the single leading cause of GLP-1 discontinuation (Truveta); the beauty equivalent is irritation, inconvenient application windows, or a routine that doesn't fit a real morning.
4. "Perceived completion" is dangerous. Patients who feel they've "done enough" stop early and lose the ground they’ve gained (Cleveland Clinic, 2026). Skin ageing and metabolic health are the same: results are conditional on continuation, not a finish line. Brand messaging built around "getting results" rather than "sustaining results" quietly trains customers to stop.

What Longevity Clinics Can Learn From Consumer Engagement Design

If medicine's failure mode is an under-designed experience around a highly effective intervention, the beauty and retail world's core competency — engagement, loyalty, and experience design - is exactly what longevity clinics are missing.

Consumer loyalty data shows what's possible when experience is designed deliberately: 90% of consumers are enrolled in at least one loyalty programme, 83% say membership influences their repurchase decisions, and beauty loyalty members spend 43% more on average than non-members (Rivo.io). Beauty retailers have spent twenty years engineering onboarding sequences, milestone rewards, personalised content cadences, and win-back flows purely to keep people engaged with a routine.

Longevity clinics, by contrast, are often still operating on a legacy medical model: a diagnostic panel, a one-time consultation, a protocol handed over on paper, and a follow-up appointment scheduled months later with almost none of the mid-cycle engagement infrastructure that keeps a beauty subscriber opening her box. The lesson is direct: the science-heavy side of the industry needs the engagement design the beauty side has already mastered, and the beauty side needs the adherence rigour and clinical measurement discipline the longevity and medical side already has. The next competitive advantage sits precisely at that intersection.

At the same time, beauty subscription models are a cautionary tale about experience alone without genuine incremental value: subscription boxes lose roughly 34% of subscribers within the first 90 days, and beauty subscription churn now averages 9.8% monthly over 70% annualised (RetentionCheck, 2026; Lifecycle Architect). Engagement tactics without a genuine outcome behind them just slow down an inevitable cancellation.

Coaching, Community, and Accountability: What Actually Moves the Needle

Across dozens of studies, one pattern recurs: outcomes improve when a human relationship sits alongside the product or protocol, not instead of it. Health coaching interventions reviewed across randomised trials showed measurable improvements in nutrition, physical activity, weight management, and medication adherence when a coach was added to standard care (health coaching pilot review). The "Supportive Accountability" model -a well-established framework in digital health explains why: human accountability increases adherence to self-directed programmes even when the human contact is minimal, because it converts a private intention into a social commitment (Supportive Accountability).

Community operates on the same mechanism at scale. This is precisely why fitness, sobriety, and chronic disease management have all converged on group and peer models over the last decade and why the most durable beauty and longevity brands increasingly look and feel like communities with a product attached, rather than products with a newsletter attached.

The Business Model Shift: Selling Products vs. Managing a Relationship

Put these threads together, and a structural shift comes into focus. The economics of consumer health are moving from a transactional model- sell a product or a treatment, move to the next customer toward a relationship model, where the business is compensated for an ongoing outcome, not a single purchase.

This shift is already evident in how longevity clinics structure revenue. Rather than charging per treatment, leading operators are building recurring membership or programme fees that fund clinical oversight, lab work, and monitoring, layered with subscription revenue for ongoing therapies — a stacked recurring-revenue model built explicitly to keep the provider (and the patient) engaged month over month rather than visit over visit (Longevity clinic business model analysis). Beauty is moving in the same direction across membership tiers, replenishment subscriptions, and loyalty ecosystems, though the churn data above shows that most of the industry is still executing this poorly.

The organisations that will win this transition are the ones that stop asking "how do we sell more units" and start asking "how do we own an outcome over 12, 24, or 60 months." That reframing changes everything: pricing, onboarding, staffing, data infrastructure, and what "success" even means internally.

Which Models Genuinely Improve Adherence and Retention?

Not every recurring-revenue wrapper delivers real behaviour change. Evidence and market data suggest a rough hierarchy:

• Pure product subscriptions (replenishment boxes) show the weakest retention on their own — high monthly churn, driven by novelty fatigue and the absence of any accountability mechanism (RetentionCheck).
• Loyalty and rewards programmes measurably lift spend and repurchase intent but don't, by themselves, drive the underlying health behaviour; they reward the transaction, not the habit (Rivo.io).
• Coaching-anchored memberships (a person checking in, adjusting the protocol, celebrating milestones) show the strongest evidence of sustained behaviour change, because they combine personalisation with the "supportive accountability" mechanism described above.
• Community-anchored models add a peer layer that keeps people engaged even when the coach or clinician isn't directly present durable, but slower and harder to scale without technology support.

The strongest models on the market increasingly stack all three: a membership fee that funds oversight, a coach or practitioner for accountability, and a community layer for belonging with the product or treatment as the entry point rather than the whole offer.

Who Owns the Long-Term Consumer Relationship?

This raises a genuinely unresolved strategic question for the industry: as consumer health shifts from products to protocols, who owns the ongoing relationship — the brand that formulated the product, the clinic that delivers the treatment, the platform that aggregates the data, or the individual practitioner or coach the consumer actually trusts?

Each has a claim, and each has a structural weakness:

• Brands have the manufacturing scale and marketing reach, but historically the weakest direct, ongoing relationship with the end consumer, especially in categories still sold through retail.
• Clinics have clinical credibility and diagnostic data, but as the loyalty statistics above suggest, often have the weakest experience design and engagement infrastructure.
• Platforms (wearables, apps, AI coaching tools) increasingly sit closest to daily behaviour and can capture the richest continuous data, but consumers are wary of platforms without a trusted human behind them.
• Practitioners and coaches command the deepest individual trust and the strongest accountability effect, but rarely have the scale, data infrastructure, or capital to own the relationship commercially.

The honest answer is that no single player currently owns it end-to-end — which is exactly why the next wave of category leaders will likely be hybrid entities: a clinical or brand foundation, a technology layer for continuous data and personalisation, and a human coaching or practitioner layer for accountability, bundled and sold as a single ongoing membership.

How AI Can Support Adherence Without Replacing the Human

AI is the connective tissue that makes this hybrid model financially viable at scale, and the recent evidence is genuinely encouraging, but with an important caveat.

Structured trials show real gains: AI-based coaching tools have been shown to boost medication adherence by 6.7% to 32.7% compared with standard care in various programmes, with hybrid AI-plus-human-mentor models reporting retention rates as high as 91% (PatientPartner). Reinforcement-learning-guided messaging has boosted medication adherence across chronic conditions by roughly 14 percentage points versus a control group by delivering the right nudge at the right contextual moment (Frontiers in Digital Health, 2026). Stanford Medicine's "My Heart Counts" programme, launched in 2026, uses an AI coach built on the decades-old Transtheoretical Model of behaviour change to tailor its messaging to exactly where a user sits on the readiness-to-change spectrum — motivating ambivalent users differently than those already acting (Stanford Medicine).

But a 2025 randomised field study of an LLM-augmented activity coach found something equally important: while the AI-augmented group reported more positive mindsets, more personalised plans, and five times more time spent engaging with the app, users overwhelmingly credited their accountability to the plans, reminders, and visual dashboards not to the chatbot conversation itself (Bloom study, arXiv 2025). In other words, AI excelled at personalisation, availability, and flexible planning, but the sense of being accountable to someone still came from structure and, ultimately, from human or human-designed touchpoints.

The practical implication for beauty, wellness, and longevity operators: use AI to personalise at a scale no human team could match , adjusting protocols in real time from wearable and diagnostic data, predicting who is about to disengage, and delivering the right message at the right moment. But keep a human- a coach, practitioner, or community- as the actual source of accountability the AI is orchestrating around. The winning formula emerging from the evidence is AI for personalisation and prediction, humans for trust and accountability, not one replacing the other.

The Next Evolution of Consumer Health

Beauty, wellness, and longevity have spent the last decade competing on the sophistication of their products and the precision of their diagnostics. The next decade will be won by whoever can close the gap between what science recommends and what consumers actually sustain, by building organisations around ongoing relationships, measurable outcomes, and genuine behaviour change, rather than around the transaction.

That is a fundamentally different kind of company to build: less "what are we selling" and more "what outcome are we responsible for, and for how long." It requires borrowing medicine's rigour around adherence, borrowing retail's mastery of engagement and loyalty, and using AI as the infrastructure that makes personalised, continuous accountability affordable at scale, with a human relationship still at the centre.

The brands, clinics, and platforms that make this shift first won't just retain more customers. They'll be able to prove, with data, that their customers are actually healthier, longer, which will become the single most valuable claim in the industry.

This topic and the research behind it will be explored further at upcoming INNOCOS summits and dinners. If your organisation is building membership, coaching, or AI-enabled adherence models in beauty, wellness, or longevity, we'd love to hear from you.